Trichostatin A (TSA)

Catalog No.S1045

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Cited by 25 Publications

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cell, 2017, 171(4):824-835.e18

PubMed: 29056338 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 485(2):454-460

PubMed: 28192116 ( click the link to review the publication )

Nat Commun, 2016, 7:10690

PubMed: 26891683 ( click the link to review the publication )

Int J Oncol, 2016, 48(6):2591-607

PubMed: 27082124 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

Am J Transplant, 2015, 10.1111/ajt.13106

PubMed: 25708614 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1586

PubMed: 25569103 ( click the link to review the publication )

J Antimicrob Chemother, 2015, 10.1093/jac/dku549

PubMed: 25558076 ( click the link to review the publication )

Mol Nutr Food Res, 2015, 59(2):189-202

PubMed: ( click the link to review the publication )

Cancer Cell, 2014, 26(4):534-48

PubMed: 25314079 ( click the link to review the publication )

EMBO J, 2014, 34(1):115-29

PubMed: 25398909 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(3):E364-73

PubMed: 24395801 ( click the link to review the publication )

PLoS Biol, 2014, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4143-64

PubMed: 25202123 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2014, 274(1):7-16

PubMed: 24200994 ( click the link to review the publication )

Life Sci, 2014, 99(1-2):31-6

PubMed: 24486299 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 445(2):320-6

PubMed: 24530917 ( click the link to review the publication )

Sci Rep, 2014, 4:4663

PubMed: 24722541 ( click the link to review the publication )

Plant J, 2013, 74(5):815-28

PubMed: 23464703 ( click the link to review the publication )

Cytokine, 2013, 65(2):121-5

PubMed: 24373940 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )
Epigenetics, 2012, 7(10):1161-72

PubMed: 22965008 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Targets

HDAC ^[1]
(Cell-free assay)

~1.8 nM

In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. ^[1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. ^[2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HEK 293	M1q0V2Z2dmO2aX;uJGF{e2G7	M1y4W\|AvP87:TR?=	M2DiNVI1cA>?	M2q4bIV1cGGwb3y=	NUK3UGpU\W6qYX7j[ZMhTU6jQzDhZ4V1gWyjdHnvckBidmRiaX7jdoVie2W\|IFXOZWMh[WK3bnThcoNmKGmwIITo[UB1d3SjbDDj[YxtKGy7c3H0[UBidmRiYYSgeIhmKGOnbHygd5Vz\mGlZR?=	M2[xelI2Pzh5MEe5
TE13	NV\UTFF6TnWwY4Tpc44hSXO\|YYm=	M{fO[\|AvO87:TR?=	NHO4O\|IzPGh?		NWTUUpBYfXBvcnXneYxifGW\|IGLBV3NHPUFibHX2[Yw>	MlrFNlU2Pzl4NkW=
TE13	NEPyZo9CeG:ydH;zbZMhSXO\|YYm=	NUXtW2Z7OC5\|zszN	Mk\vNlRp		MYHpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9v	NWnNTolsOjV3N{m2OlU>
MEFs	NGK4Z5dHfW6ldHnvckBCe3OjeR?=	MUO1{txO	MU[xOog>		NHi0XGJqdmO{ZXHz[ZMhfGinIFXQSWMh[XS2YXPocYVvfCxiVHnyJIRmdGm4ZYL5JIFv\CC2aHWg[YZncWOrZX7jfUBw\iCyZXTld5RidCCob4LtZZRqd25?	MVKyOVQ5OjZ\|NB?=
SW480	MXzGeY5kfGmxbjDBd5NigQ>?	MnroNE4y\|ryP	NUTwbXNOPDiq	MnrNSG1UVw>?	NXr4fYpoemW4ZYLz[ZMhTU2W	MY[yOVQ{PDl7Nx?=
PC3	M320dmZ2dmO2aX;uJGF{e2G7	M4DPSlAvOc7:TR?=	MlvkOFhp	M3L1RmROW09?	MoridoV3\XK\|ZYOgSW1V	NX3wfGVrOjV2M{S5PVc>
SW480	M2LJR2Z2dmO2aX;uJGF{e2G7	MYWwMlHPxE1?	NWr3ZW1kPDiq	M3uxfWROW09?	NGLWT2NifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36=	NX7yWYVZOjV2M{S5PVc>
PC3	MkPUSpVv[3Srb36gRZN{[Xl?	MX6wMlHPxE1?	MoHkOFhp	MUPEUXNQ	M{[xfYF1fGWwdXH0[ZMhcW64YYPpc44h[W6mIH3p[5JifGmxbh?=	MmXjNlU1OzR7OUe=
SW480	NYPne4NqTnWwY4Tpc44hSXO\|YYm=	MXKwMlHPxE1?	MUC0PIg>	NXHBbGZSTE2VTx?=	MXnpcoR2[2W\|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz	NUXmTYN2OjV2M{S5PVc>
PC3	NEe3cZNHfW6ldHnvckBCe3OjeR?=	MljkNE4y\|ryP	Mn24OFhp	MoLZSG1UVw>?	MlTsbY5lfWOnczDpcoNz\WG\|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>?	NF:ze4ozPTR\|NEm5Oy=>
A431	M1nnU2Fxd3C2b4Ppd{BCe3OjeR?=	Ml;yNk8yOC93MD:xNFBvVQ>?	M1fBZlQ5cA>?	MWrEUXNQ	NEf2O5FqdmirYnn0d{B1cGViY3XscEBoem:5dHi=	MUGyOVM4OTB4OR?=
A431	MUHGeY5kfGmxbjDBd5NigQ>?	MYO1NI5O	NE\UPXczNzZxMUKvNlRp	MlfFSG1UVw>?	NYHxPIpH[WO2aY\heIV{KHB{MTDhcoQhcW6qaXLpeJMhSVSIMzDlfJBz\XO\|aX;u	MYmyOVM4OTB4OR?=
MDA-MB-231	MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVewMVYxOG6P	NUS1c5h1OjSq	NHXjeY9FVVOR	MYLJR\|UxKG:oIEGwNI5O	MXKyOVE6Ojd{MR?=
MCF7	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1uxWVAuPjBybl2=	MYeyOIg>	NV\WWlA1TE2VTx?=	NGPk[HJKSzVyIH;mJFc2dk1?	NWHmVZk6OjVzOUK3NlE>
SKOV-3	NH20WGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVWxMVEx\|ryP	NEPQNpAzPGh?	MYXEUXNQ	MkXiTWM2OCCxZjC1MlbPxE1?	M1;QbVI2OTZ7NEmx
A549	NFrpPZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYmxMVEx\|ryP	NFywcIQzPGh?	M{[2bGROW09?	M3[yW2lEPTBib3[gN{4z\|ryP	MkL4NlUyPjl2OUG=
SKOV-3	NYTaWmhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXn0[JI4OC5zLUJOwG0>	NEjYflU1QGh?	MnXhSG1UVw>?	MXPJR\|UxKG:oIECuO:69VQ>?	NELrSVgzPTF4OUS5NS=>
A549	Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojnNE4yNTIQvF2=	M3vob\|Q5cA>?	MV7EUXNQ	M1;2XGlEPTBib3[gNE4zQM7:TR?=	NVPM[oRQOjVzNkm0PVE>
SKOV-3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLZUFE5OC5yMT2wMlnPxE1?	NGjhXHg4Omh?	MVTEUXNQ	MnjhTWM2OCCxZjCwMlMz\|ryP	MWGyOVE3QTR7MR?=
A549	MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\hNE4xOS1yLkpOwG0>	M4O2elczcA>?	MU\EUXNQ	NXO1Toc4UUN3MDDv[kAxNjB4zszN	NGT3[YwzPTF4OUS5NS=>
HeLa	M1[wd2Z2dmO2aX;uJGF{e2G7	NFnLNWozPTCwTR?=	M4LoelE3cA>?	MYfEUXNQ	M4LOZ4lv[3KnYYPld{BEYVBzQUGgcXJPSSCneIDy[ZN{cW:wwrC=	MYeyOVEyPjZ6OB?=
CNE2	NGfvS41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPXSFlpOTByLU[wNI5O	NX3MUZpyOjRxNEivO\|Jp		M{Wye4lvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	M1jQT\|I1QTZ7OUCx
PC3	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvFNVAxNTFyMEDuUS=>	NG\VUFgzPGh?		M3Po[GlEPTBib3[gN\|Axdk1?	NGSzdWwzPDh3NE[1PC=>
LNCaP	NHf0e3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvvNVAxNTFyMEDuUS=>	MkLHNlRp		MXPJR\|UxKG:oIEOwNI5O	NHjifIwzPDh3NE[1PC=>
HeLa	NUi5XoRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlO4Nu69VQ>?	MkXGOFhp		M4Tqb4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDhZo92fCB{NTW=	NV3DNZhZOjR6NE[xN\|U>
HMEC-1	MkHESpVv[3Srb36gRZN{[Xl?	MVqzNFBvVQ>?	M3SxSVI1cA>?		NH\Z[nZqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZtMgWmVITlJ\|wrDtVm5C	M{\o[FI1PzFyNkOx
HeLa	NFLzNWdHfW6ldHnvckBCe3OjeR?=	NVS0VXpoOW2P	NIHSNncxNjWq		MYfhZo9tcXOqZYOgeIhmKHSxdHHsJGhFSUNiYXP0bZZqfHl?	NE\BV5AzPDdyN{S3OC=>
ACP02	NUPJUWZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzVNlUxNzN3MD:1NFBvVQ>?	M{C0[lI1cA>?		M3HDeIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1?	NVjxb5NWOjR4Nki1OFc>
ACP03	MmC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXkTYJFOjVyL{O1NE82ODCwTR?=	MYGyOIg>		M{noUoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1?	NXqwSGt2OjR4Nki1OFc>
U87 GBM	M1[3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTNeWoyODBxM{CwM\|UxOCCwTR?=	NGPsVWs4OiCq	MkfFNVAxLSCndHjhco9t	NWfWeoJPemWmdXPld{Bu\WGwIHPlcIwhdnWvYnXyJIJ6KDNzLDC1OEwh[W6mIEW4xsAm	MUeyOFQ3PDh2MR?=
U87 GBM	NF3iU3dHfW6ldHnvckBCe3OjeR?=	NV:zUGx{OTByL{WwNEBPdQ>?	MoXEOFghcA>?	MYGxNFAmKGW2aHHuc4w>	NXeyO\|hiUW6mdXPld{BU\W6nc3PlcoNmNUyra3WgRYx1\XKjdHnvcpMhcW5iToXjcIVieiCPb4LwbI9td2e7	Mnn0NlQ1PjR6NEG=
RPE	NUXSVlhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTnPWQxNjJxMD60M\|AvQC9zIN88US=>	MnW4NlQwPDhxN{KgbC=>	M2XIVmROW09?	M{HUfolvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIJ6KGOnbHygZ5lkdGViYYLy[ZN1	NFzyeGwzPDR3Nk[wNi=>
HT29	NEnTTYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7UUmwyQDBibl2=	Mmi3O\|IhcA>?		MX3JR\|UxKG:oIEG4NEBvVQ>?	M3nzdFI1OzZ6Mk[1
hMSCs	NW[xR5BUTnWwY4Tpc44hSXO\|YYm=	NUTDPYxCPi5{NTDuUS=>	NF\GNmYzPCCq	M3K3dGROW09?	NUTL[HN5e3SjYnnsbZpmeyCKaYP0c45mKEGlZYT5cIF1cW:wIHHu[EB1cGViRYjwdoV{e2mxbjDv[kBRdHW{aYDveIVvfCCJZX7ldy=>	Mmr0NlQ{OTJ\|NU[=
Huh7	MXfGeY5kfGmxbjDBd5NigQ>?	NFH1ZXoxNjFxMD61M\|EvOCEQvF2=	MY[yOIg>		MmnId5VxeHKnc4Pld{B[XEiGQ{Kg[4Vv\SCneIDy[ZN{cW:w	MnLXNlQzPjl4N{K=
SKOV3	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\nZolTOC5yNT2yJO69VQ>?	NGrxPFMyOC9{ND:0PEBp	NWnBNlRJTE2VTx?=	MYjt[YRq[XSnczDndo94fGhiYYLy[ZN1KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	MXOyOFIzOzhyMR?=
A2780	M3LQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nrRVAvODVvMjFOwG0>	NILtZ2MyOC9{ND:0PEBp	NIfTRpJFVVOR	NEHrSGxu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?=	M2PXWlI1OjJ\|OECx
SRA01/04	Ml\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrkfIsxNjJizszN	NXfWVZhtPDhiaB?=	NFzUXnJFVVOR	Mnf0d5VxeHKnc4Pld{Bk\WyuIIDyc4xq\mW{YYTpc44hfGi{b4XnbEB{fXCycnXzd4lv\yC2aHWgVGk{Uy:Da4SsJJA{QE2DUFugZY5lKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfZM>	NF31epQzPDF3N{i3PC=>
HLEB3	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXu1eXBiOC5{IN88US=>	NFi5bmw1QCCq	NFP3NnlFVVOR	NXrU[Gxve3WycILld5NmeyClZXzsJJBzd2yrZnXyZZRqd25idHjyc5VocCC\|dYDwdoV{e2mwZzD0bIUhWEl\|Sz;Bb5QtKHB\|OF3BVGsh[W6mIFXST\|EwOiC\|aXfuZYxqdmdicHH0bJdigXN?	MmXjNlQyPTd6N{i=
SRA01/04	NWexfVJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4D6VlAvPC9yLkig{txO	MWi0PEBp	M1rTWWROW09?	NIjueJRqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	MXKyOFE2Pzh5OB?=
HLEB3	M4TlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4CyTVAvPC9yLkig{txO	NEHseJo1QCCq	M1r0SWROW09?	MY\pcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NELBWJIzPDF3N{i3PC=>
HCT116	NI\q[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PlZ\|AvOiEQvF2=	NXXoe\|N{OTJiaB?=		M4fSPIVvcGGwY3XzJINmdGxiYYDvdJRwe2m\|IHnu[JVk\WRiYomgdoFlcWG2aX;u	Ml;HNlQyOjJ{M{G=
CA46	NHPTOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2KxWFMwPi9zMj:yOE81QCCwTR?=	M{KxNFQ5KGh?		NUHsTXo3cW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDheEAzPCCjbnSgOFghdk4EoB?=	M2HXOlI1ODZ2OUWx
PMNs	NWjxOWViTnWwY4Tpc44hSXO\|YYm=	MW[zNEBvVQ>?	Mn7BOFghcA>?		MnPEbY5pcWKrdIOg[YZn\XKxY4n0c5NqeyxiSFTBR{Bi[3Srdnn0fUBidmRiUnHjJIFkfGm4aYT5	NVfFdmZzOjN7OEi2NVc>
H1299	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XVfFHDqM7:TdMg	NU\YNG0{OjRxNEivO\|IhcA>?	Mnu0[ZRp[W6xbB?=	MorvbY5kemWjc3XzJINmdGxiZHXheIgh[W[2ZYKgNlRp	M3r5cFI{QTF4NkC5
A549	MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MViwMlI2NzBwNT:xJO69VQ>?	MUSyOE81QC95MjDo	NEjKbYJmfGijbn;s	MV;pcohq[mm2czD0bIUh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdiCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz	NU\JN3F7OjN6Nke5PVE>
H1299	NVnIeXNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI[x[\|AxNjJ3L{CuOU8yKM7:TR?=	MUGyOE81QC95MjDo	M13kRoV1cGGwb3y=	NVXieWxUcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvKGOxbnPlcpRz[XSrb36gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?=	NEK3eYgzOzh4N{m5NS=>
A549	NFL1cYxCeG:ydH;zbZMhSXO\|YYm=	NVLWNHRrOC53L{Gg{txO	NHPYU5I1QCCq	Mki5[ZRp[W6xbB?=	MlnBbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	M4LYOVI{QDZ5OUmx
H1299	Mk\ERZBweHSxc3nzJGF{e2G7	NHXDUZYxNjVxMTFOwG0>	NXqzb5F4PDhiaB?=	NWDBcYpi\XSqYX7vcC=>	NELLUFlqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	NGDFOZUzOzh4N{m5NS=>
SUM149PT	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnxWFkzOi95LkWvNVAh\|ryP	NE\BWXA1QCCq	M3jkWGROW09?	NWDRPIdMcW6mdXPld{Bk\WyuIHTlZZRpKGG2IEKg{txOKGmwc3Xud4l1cX[nbIm=	M1H0N\|I{Pzl{NkO4
SUM190PT	NUnNRmQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUG1NE8yODBxMkWwJI5O	M2LmfVQ5KGh?	NUTqVYp3TE2VTx?=	Mn;DbY5lfWOnczDj[YxtKGSnYYToJIF1KDVyIH7NJJNmdnOrdHn2[Yx6	MXWyN\|c6OjZ\|OB?=
HCT1	M1vMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYOwMlIwOS5yL{WuNEDPxE1?	MX2xNk8zPC9\|Nj:0PEBp		NG\x[WdqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=>	NX3MZYc3OjN5N{CwNFA>
Lovo	NEXzNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLhVGwxNjJxMT6wM\|UvOCEQvF2=	M1Hw[VEzNzJ2L{O2M\|Q5KGh?		NITTOmVqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=>	NHLvO3QzOzd5MECwNC=>
AGS	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvBV254OC5yMUWtNUDPxE1?	NVHm[3duPzJiaB?=		M4\5WIlv\HWlZYOgZ4VtdCCmZXH0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5	MlXyNlM4PDVyMkS=
Huh7	M2\BeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLFNUDPxE1?	MofaNlQhcA>?	NF7zb3VFVVOR	MlTzdoVlfWOnczDhZo92fCB{MDWgeoli[mmuaYT5xsA>	NUDJU4JoOjN4NEO5N\|M>
ECC1	NE\uV2JHfW6ldHnvckBCe3OjeR?=	NIfMXGk2ODBibl2=	MnjWOUBl	M3W2[mROW09?	MYnpcoR2[2W\|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>?	NGTmXVczOzV\|MEe2PS=>
HEC1A	MlTRSpVv[3Srb36gRZN{[Xl?	NIniZo02ODBibl2=	M4PjVFUh\A>?	M4XPdWROW09?	MUfpcoR2[2W\|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>?	MVSyN\|U{ODd4OR?=
EN1	NFXDUJJHfW6ldHnvckBCe3OjeR?=	MmXPOVAxKG6P	NETtSJQ2KGR?	MlTvSG1UVw>?	MoC2bY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN?	NH\lXpEzOzV\|MEe2PS=>
MFE296	NIHjbGRHfW6ldHnvckBCe3OjeR?=	MlfUOVAxKG6P	NILTdWk2KGR?	MUDEUXNQ	MUPpcoR2[2W\|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>?	MkCwNlM2OzB5Nkm=
HASMCs	MULGeY5kfGmxbjDBd5NigQ>?	NXzLTXZjOC13MECgcm0>	Mmf1OkBl		MljP[I94di2{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFHER{BidmRiY3XscEB3cWGkaXzpeJk>	M13zXFI{PTF6NE[3
U373	MmSySpVv[3Srb36gRZN{[Xl?	MnX2NE4zPS9yLkWvNUDPxE1?	NVv0SHBHOjRiaB?=		M2fDT4lv[3KnYYPld{BRWi2EIHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOWF7[WSF	MWmyN\|Q4PDF5MR?=
ARN8	Mk\6SpVv[3Srb36gRZN{[Xl?	MnTNNE4xPS1{IN88US=>	NY\XenRKOjRiaB?=		M4T0e5Jm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDwOVMu\GWyZX7k[Y51KGenbnXzJIJ6KE63dHzpck0{	NFXrcYYzOzR5MEW0NC=>
MCF7	MVvGeY5kfGmxbjDBd5NigQ>?	NH;pSnoxNjB3LUKg{txO	NY\oelV2OjRiaB?=		NWTxeoZIemWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN?	Mmm3NlM1PzB3NEC=
H1299	NXfpNHhLTnWwY4Tpc44hSXO\|YYm=	NWD6eWk2OC5\|M,MAl\|HDqML3TR?=	NWLSNlJnOjRxNEigbC=>	MVLEUXNQ	MYjpcoNz\WG\|ZYOgSU1k[WSqZYLpckBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7	NGPwdmgzOzR4MUm3OS=>
H1299	MlTDSpVv[3Srb36gRZN{[Xl?	NIPJVIUxNjVizszN	Mo\BOFghcA>?	M1vXeWROW09?	M1Xuc4lvcGmkaYTzJJRp\SCvaXfyZZRwenlicH;0[Y51cWGuIHPvcYJqdmVid3n0bEB{cWyrYnnubY4>	MoLYNlM1PjF7N{W=
H1299	MWDGeY5kfGmxbjDBd5NigQ>?	M3\mWVAvPSEQvF2=	NX7IZ2ZYPDhiaB?=	NVvjdo0yTE2VTx?=	NYDxR2FUcW6qaXLpeJMhfGinIHnueoF{cX[nbnXzd:KhKGOxbXLpcoUhf2m2aDDzbYxq[mmwaX6=	MoLSNlM1PjF7N{W=
MG-63	NIHXb2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3sVHdROC5\|IN88US=>	NEXIdHkyOi17NjDo	M2ji[GROW09?	MYPpcohq[mm2czD0bIUh[2WubDDndo94fGhiY3:teJJm[XSvZX70JJdqfGhibXX0[o9zdWmw	Mn24NlM1PTF6MUe=
LM8	M2exS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1[3Z\|AvOyEQvF2=	M3P5flEzNTl4IHi=	Ml7xSG1UVw>?	M4DKWolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDjc{11emWjdH3lcpQhf2m2aDDt[ZRnd3KvaX6=	NG\jUZAzOzR3MUixOy=>
K562	NUX5bZdKTnWwY4Tpc44hSXO\|YYm=	MnvMNE42KM7:TR?=	NWLFbZhwOjRiaB?=	MoS1[ZRp[W6xbB?=	M3XteYRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv	Mn:2NlM1OzB7NUe=
HEL	NYfOV2pPTnWwY4Tpc44hSXO\|YYm=	M3;uelAvPSEQvF2=	M2HBXFI1KGh?	NYS0NGtO\XSqYX7vcC=>	MUTk[YNz\WG\|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=>	NWL0cnBMOjN2M{C5OVc>
HL60	MXXBdI9xfG:\|aYOgRZN{[Xl?	MYWxJO69VQ>?	NXvoVFhOOjRiaB?=		Ml;kbY5lfWOnc9MgZ4VtdCCmZXH0bC=>	MXOyN\|QxODVzOR?=
KG1	NHfrNVlCeG:ydH;zbZMhSXO\|YYm=	NYHaPIdxOSEQvF2=	NXrvZ2NQOjRiaB?=		NE\ZfZJqdmS3Y3XzxsBk\WyuIHTlZZRp	M1vQWlI{PDByNUG5
Kazumi	MnG5RZBweHSxc3nzJGF{e2G7	NX;zUoUxOSEQvF2=	M3SwUlI1KGh?		MoizbY5lfWOnc9MgZ4VtdCCmZXH0bC=>	MYiyN\|QxODVzOR?=
K562	NFLBfllCeG:ydH;zbZMhSXO\|YYm=	NG\rPZAyKM7:TR?=	NYLJ[HNGOjRiaB?=		M4DGV4lv\HWlZYRCpINmdGxiZHXheIg>	NE\kemszOzRyMEWxPS=>
THP1	MV3BdI9xfG:\|aYOgRZN{[Xl?	Mn;LNUDPxE1?	NILjXGIzPCCq		Ml2xbY5lfWOnc9MgZ4VtdCCmZXH0bC=>	M3jrXlI{PDByNUG5
SH-SY5Y	NXzwVVZRTnWwY4Tpc44hSXO\|YYm=	NH;qS2MzPTBibl2=	M4PPc\|E3KGh?		MkLFZ4hidmenczDlfJBz\XO\|aX;uJJBifHSncn6gc4Yh\2WwZYOgbY53d2y4ZXSgbY4h[2ixbHXzeIVzd2xic4nueIhme2m\|LDD1dJRic2ViYX7kJIVn\my3eB?=	MYiyN\|MzPjR{Mh?=
HEK293	MnfFSpVv[3Srb36gRZN{[Xl?	NHnvfZgyKML3TdMg	MUGxPEBpyqB?		MWHpcohq[mm2czD0bIUhc2GuaYLpck04NW2nZHnheIVlKHKnY4L1bZRu\W62IH;mJJN6dnCqaXzpck0yKGGpZ4Ll[4F1\XNiaX70c{Bi\2e{ZYPvcYV{	M3jEelI{Ojh2OES4
HTK	NHT0cmdHfW6ldHnvckBCe3OjeR?=	NXXweXJlPDByIH7N	MmTwO\|IhcA>?		MYDpcohq[mm2czDUS2Yu\|rMkgKPJcoR2[2WmIF35c4Zq[nKxYnzhd5QhTGmoZnXy[Y51cWG2aX;u	MXmyN\|I5PDByMh?=
HTK	MVnGeY5kfGmxbjDBd5NigQ>?	MUexNFAuQDBybl2=	NEK2bYc4OiCq		MVPicI9kc3NiVFfGMe6z6oDVSX7keYNm\CCUT2OgZY5lKEh{T{NCpGFk[3WvdXzheIlwdg>?	NGTBT44zOzJ6NECwNi=>
Caco-2	MYXGeY5kfGmxbjDBd5NigQ>?	MYexJOK2VcLi	M3jabVI1KGh?		Mn2x[IVkemWjc3XzJHNGWlRicILveIVqdiCneIDy[ZN{cW:w	MWmyN\|E6PTB5MB?=
HeLa	M1\tcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HPdlExOCCwTR?=	NIS5Vm8zPCCq	NGKw[VlFVVOR	MWDJR\|UxKG:oIEGwNI5O	MmTFNlMyPjV5NEi=
HeLa	MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnDc2E1OCCwTR?=	NIe4XpQ1QCCq	MYnEUXNQ	M4Tz[2lEPTBib3[gOFBvVQ>?	NV33WIoxOjNzNkW3OFg>
HeLa	M4rqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVftOmZJOjBibl2=	NVzwemdtPzJiaB?=	NEXYV3FFVVOR	NVPCd41WUUN3MDDv[kAzOG6P	M1LP[lI{OTZ3N{S4
HeLa	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXwb3hHOTBxM{CvOVAhdk1?	NXHPbWxHPzJiaB?=	NFPhfoNFVVOR	NX7ZNngzcW6lcnXhd4V{KHSqZTDueY1j\XJib3[gUW1RKCkQlN8ocUkhdG:\|czDj[YxteyCmb4PlJIRmeGWwZHXueIx6	NWLyb\|hMOjNzNkW3OFg>
MDA-MB-231	NYXUSlRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzkNlUuPDByIH7N	NHr3R3o1QCCq		NXn6[ZJjUUN3MDDv[kAzPjNwMn7NxsA>	NYfLem4zOjNyNUWxPVg>
MCF-7	M3P0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVWyOU01ODBibl2=	NGjwdWw1QCCq		NUC4SGJHUUN3MDDv[kAzOjBwNH7N	M{XDUlI{ODV3MUm4
ECC-1	NHX5TGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XON\|ExOCCwTR?=	NHfhVlgzPCCq	NIfT[pJmfGijbn;s	Mn3tbY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzVn	NXPjN5NPOjNyMki4NFM>
HEC-1A	M3TSdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLDNVAxKG6P	MlvLNlQhcA>?	MmPy[ZRp[W6xbB?=	NF24NWFqdmO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[XCxcITveIlkKG63Y3zlbUB1dyB\|OTW=	MWKyN\|AzQDhyMx?=
NHAC-kn	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoruNVAwOTByL{WwNEBvVQ>?	M3jQc\|EzKGh?	MVHEUXNQ	MnrKTWM2OCCxZjC1NFBvVQ>?	MkHvNlMxOTd6N{G=
A549	M4\0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYeyOVAhdk1?	NEi4eGQ3NTd{IHi=	NVXnSngzTE2VTx?=	MoDTZ4F2e2W\|IHGg[5Jm[XSncjDpcohq[mm2b4L5JIVn\mWldDDjc41jcW6nIIfpeIghXFiWIH;yJIVzdG:2aX7pZi=>	MnviNlI6QTR5OEC=
MG-63	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HZ[FMxOCCwTR?=	MV2xNkBp	M1zKb2ROW09?	NUPX[WxOcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDh4JR?=	MY[yNlc6QTN\|OB?=
MG-63	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXGbo8{ODBibl2=	NUT6SZF4OjRiaB?=	NIq2RYhFVVOR	NVvuVFA1cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDZ5JR?=	NEjGNlUzOjd7OUOzPC=>
MG-63	MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmTPN\|AxKG6P	NUfab5R{PDhiaB?=	NWDlU2JUTE2VTx?=	NYLVeVA5cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDV4JR?=	MkHINlI4QTl\|M{i=
HL60	NI\Yd\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHr6WHIyPTBvM{WwJI5O	MkjpNlQhcA>?		M4Ww[olv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0>	NIfQcYkzOjd3M{ezPS=>
U937	M3y1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTlNVUxNTN3MDDuUS=>	NH;rVo0zPCCq		MV7pcoNz\WG\|ZYOgZ4VtdCCjcH;weI9{cXQEoIfo[Y4h[2:wY3XueJJifGmxboOgbIlocGW{IIToZY4hOjVyIH7N	M{iyOFIzPzV\|N{O5
SCC-6	Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnTbGxsOjByLUOyNFAhdk1?	M{XvU\|EzNzJ2L{S4JIg>	M4q4fWROW09?	M{jhR4lvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJI9nKFOFQz22JINmdGy\|IHnuJIEh\G:\|ZT2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?=	NH\Qc\|gzOjV3MkOyNS=>
U87	M1K3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUKxNFAuOzByIH7n	NXzMemF[OjRiaB?=		NVjIdpdqcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDd{JTCgZZQhOjBybne=	MUmyNlI4ODh2OR?=
K562	NFPieXRHfW6ldHnvckBCe3OjeR?=	M4rGNlEh\|ryP	MVexNkBp	M17QS2ROW09?	MkDq[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK=	Mn7oNlIyPzlzOUi=
Reh	M2HaNGZ2dmO2aX;uJGF{e2G7	MWiwMlMwOSEQvF2=	MXSxNkBp	MXrEUXNQ	M1XXWoVvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh\|IHnu[JVk\WRiYomgOU1igmFvQ3TS	NUDWb3VMOjJzN{mxPVg>

... Click to View More Cell Line Experimental Data

In vivo

Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. ^[1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. ^[5]

Protocol

Kinase Assay: ^[1]	+ Expand In vitro HDAC activity: Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×10⁵ cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 10⁶ cpm) of [³H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [³H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [³H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research: ^[1]	+ Expand Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM Incubation Time: 96 hours Method: Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU Formulation: Dissolved in DMSO Dosages: ~5 mg/kg/day Administration: Injection s.c. (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	23 mg/mL (76.05 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Trichostatin A (TSA) SDF

Molecular Weight	302.4
Formula	C₁₇H₂₂N₂O₃
CAS No.	58880-19-6
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03839758	Not yet recruiting	Shoulder Arthritis	Université de Montréal	May 2019	Not Applicable
NCT03839758	Not yet recruiting	Shoulder Arthritis	Université de Montréal	May 2019	Not Applicable
NCT03858517	Not yet recruiting	Shoulder Arthroplasty	Stryker Trauma GmbH	April 2019	--
NCT03858517	Not yet recruiting	Shoulder Arthroplasty	Stryker Trauma GmbH	April 2019	--
NCT03735173	Recruiting	Arthropathy Shoulder\|Shoulder Pain\|Shoulder Osteoarthritis\|Shoulder Arthritis\|Shoulder Arthropathy Associated With Other Conditions\|Necrosis of Bone\|Arthritis\|Inflammatory Arthritis	Mayo Clinic	December 1 2018	Not Applicable
NCT03735173	Recruiting	Arthropathy Shoulder\|Shoulder Pain\|Shoulder Osteoarthritis\|Shoulder Arthritis\|Shoulder Arthropathy Associated With Other Conditions\|Necrosis of Bone\|Arthritis\|Inflammatory Arthritis	Mayo Clinic	December 1 2018	Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?
Answer:
Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products5

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Vorinostat (SAHA, MK0683)

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.
Entinostat (MS-275)

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Trichostatin A (TSA)

Cited by 25 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Trichostatin A (TSA) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Choose Your Country or Region

By Signaling Pathways

By product type

Trichostatin A (TSA)

Cited by 25 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Trichostatin A (TSA) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)